Med-Fine Capital

Med-Fine Capital, with offices in Shanghai and Beijing, specializes in investments in healthcare and life sciences. Our management team boasts a global perspective, deep industry expertise, extensive resources, and professional investment experience. We manage several RMB funds and USD funds, focusing on early-stage value and on-track opportunities discovery in biotech, device, diagnostics, digital and services. To date, we have invested in approximately 70 companies, including Hanyu Medical, Mabworks, ImmVira Pharma, Zion Pharma, LYNK Pharmaceuticals, Eccogene, Pharma Legacy, MagAssist, Alebund, Allorion Therapeutics, SAFE Pharmaceutical, Arthrone Technology, AccuPulse, and SMJH-Bio. Guided by our vision "to be the bridge between nations and shape the future of life sciences" and our mission "to leverage capital to drive healthcare innovation," we uphold the values of "client first, talent first, quality first, and trust always.” By combining decentralized investment with systematic operation, Med-Fine Capital is dedicated to becoming a leading, platform-based international investment institution with exceptional competitiveness and a strong reputation.